Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 6/20 | 0.47 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.46 |
| ▸ | PTPRO | Q16827 | 1/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.41 |
| ▸ | STAT3 | P40763 | 1/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | MMP12 | P39900 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1857817 | 0.90 | FFAR1 (0.50) | PTGESPTPN11PTPROFFAR1FFAR4 | |
| SCHEMBL4671737 | 0.89 | MMP2 (0.49) | PTGESPTPN11PTPROFFAR1FFAR4 | |
| SCHEMBL4967354 | 0.85 | PTGES (0.42) | PTGESPTPN11PTPROFFAR1FFAR4 | |
| SCHEMBL1855022 | 0.84 | FFAR1 (0.49) | PTGESPTPN11PTPROFFAR1FFAR4 | |
| SCHEMBL1853713 | 0.84 | FFAR1 (0.49) | PTGESPTPN11PTPROFFAR1FFAR4 | |
| SCHEMBL1853166 | 0.84 | FFAR1 (0.49) | PTGESPTPN11PTPROFFAR1FFAR4 | |
| SCHEMBL1852821 | 0.83 | PTGES (0.59) | PTGESPTPN11PTPROFFAR1AKR1C3 | |
| SCHEMBL1851285 | 0.82 | PTPN11 (0.42) | PTGESPTPN11PTPROFFAR1FFAR4 | |
| SCHEMBL6721403 | 0.81 | PTPN11 (0.41) | PTGESPTPN11PTPROFFAR1FFAR4 | |
| SCHEMBL4672519 | 0.79 | PTPN11 (0.48) | PTGESPTPN11PTPROFFAR1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207722-A1 | Glepp-1 Inhibitors in the Treatment of Autoimmune and/or Inflammatory Disorders | LABORATORIES SERONO SA (CH) | 2008-08-28 | — | — | US | claimed |
| EP-1904048-A1 | GLEPP-1 INHIBITORS IN THE TREATMENT OF AUTOIMMUNE AND/OR INFLAMMATORY DISORDERS | LABORATOIRES SERONO S.A. (CH) | 2008-04-02 | — | — | EP | claimed |
| WO-2007009959-A1 | GLEPP-1 INHIBITORS IN THE TREATMENT OF AUTOIMMUNE AND/OR INFLAMMATORY DISORDERS | LABORATOIRES SERONO S.A. (CH) | 2007-01-25 | — | — | WO | claimed |
| US-20080207722-A1 | Glepp-1 Inhibitors in the Treatment of Autoimmune and/or Inflammatory Disorders | LABORATORIES SERONO SA (CH) | 2008-08-28 | — | — | US | disclosed |
| EP-1904048-A1 | GLEPP-1 INHIBITORS IN THE TREATMENT OF AUTOIMMUNE AND/OR INFLAMMATORY DISORDERS | LABORATOIRES SERONO S.A. (CH) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007009959-A1 | GLEPP-1 INHIBITORS IN THE TREATMENT OF AUTOIMMUNE AND/OR INFLAMMATORY DISORDERS | LABORATOIRES SERONO S.A. (CH) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207722-A1 | Glepp-1 Inhibitors in the Treatment of Autoimmune and/or Inflammatory Disorders | PPP1R1B, PPP5C, PPP3CA | PTGES 999/4885PTPN11 458/4885PTPRO 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.